TP73 (Ab-99) Antibody

What is TP73 and what role does it play in cellular function?

TP73 is a member of the TP53 gene family that produces multiple protein isoforms through alternative promoters, alternative translation initiation, and alternative splicing mechanisms. The full name of this protein is tumor protein p73, with a calculated and observed molecular weight of 70 kDa . The protein plays critical roles in cellular processes related to development, differentiation, and tumor suppression.

TP73 isoforms can be broadly categorized into two main types based on their N-terminal structure:

• TAp73 isoforms: Contain a p53-like transactivation domain

• ΔTAp73 isoforms: Lack this transactivation domain

These variants have distinct and sometimes opposing biological functions. Research has demonstrated that TAp73 serves as a marker of multiciliated epithelial cells, while ΔTAp73 functions as a marker of non-proliferative basal/reserve cells in squamous epithelium . This differential expression pattern suggests specialized roles in tissue homeostasis and cellular differentiation.

How do the different TP73 isoforms vary structurally and functionally?

TP73 produces multiple isoforms with distinct biological functions through several mechanisms:

N-terminal variants:

• TAp73: Contains the transactivation domain and generally has tumor-suppressive functions

• ΔTAp73: Lacks the full transactivation domain and may have oncogenic properties or independent functions

• ΔNp73: A specific type of N-terminal variant, though recent research suggests this is a minor form in human tissues

C-terminal variants:

• p73α: The most common variant in human tissues

• p73β, p73γ, and others: Generated through alternative splicing of C-terminal exons

These structural differences translate into functional variations. For example, TAp73 and ΔTAp73 show distinct cellular distributions: TAp73 is predominantly found in multiciliated cells of tissues like bronchus, fallopian tube, and secretory endometrium, while p73α (which can contain either TA or ΔTA N-termini) is more widely expressed, including in basal layers of squamous epithelia .

The isoforms can have differential protein stability, potentially through the action of various ubiquitin E3 ligases that target specific variants .

How do researchers validate TP73 antibody specificity across isoforms?

Rigorous validation of TP73 antibody specificity is essential due to the complexity of isoform expression. The recommended validation approach includes:

• Western blotting with overexpressed isoforms:

  • Testing antibodies against lysates of cells transfected with expression vectors for each TP73 isoform

  • Checking for cross-reactivity with related family members (p53, p63 isoforms)

  • Confirming recognition of appropriate molecular weight bands

• Immunohistochemistry validation:

  • Using paraffin-embedded cell pellets of cells transfected with different p53 family proteins

  • Confirming nuclear staining pattern only in cells expressing the target isoform

  • Verifying absence of staining in cells expressing other family members

• Epitope mapping:

  • Techniques like phage display epitope mapping can identify the precise epitope sequence

  • For example, the TAp73-1.1 antibody recognizes the YFDLP sequence (amino acids 28-32 of TAp73)

  • The ΔNp73-1.1 antibody recognizes the YVGDP sequence (amino acids 3-8 of ΔNp73)

This multi-faceted validation approach ensures that researchers can confidently distinguish between closely related isoforms and family members.

What are the optimal conditions for using TP73 antibodies in Western blotting?

Successful Western blotting with TP73 antibodies requires careful optimization of several parameters:

Sample preparation considerations:

• Cell lysis buffers should preserve protein integrity while efficiently extracting nuclear proteins

• Denaturation conditions must be optimized to ensure proper epitope exposure

• Loading controls should be selected based on the experimental context

Detection systems:
Western blots detecting TP73 have been successfully performed on multiple cell lines, including:

• MCF-7 cells

• HeLa cells

• HEK-293 cells

• Jurkat cells

• HSC-T6 cells

• NIH/3T3 cells

• RAW 264.7 cells

Important note on isoform detection: When analyzing Western blots, be aware that different TP73 isoforms may show variable expression levels. For example, transfection experiments have shown that ΔNp73 proteins may appear at higher levels than TAp73, and TAp73β and TAp73γ may show higher expression than TAp73α, potentially due to differential protein stability .

How can TP73 antibodies be effectively used in immunohistochemistry (IHC)?

Successful immunohistochemical detection of TP73 isoforms requires careful attention to methodology:

Sample preparation:

• Formalin-fixed, paraffin-embedded (FFPE) tissues are suitable for TP73 antibody staining

• Antigen retrieval methods should be optimized for nuclear antigens

• Positive and negative controls should be included in each staining run

Antibody selection based on target isoform:

• For detection of all p73α variants (including both TAp73α and ΔNp73α), use p73α-specific antibodies

• For specific detection of TAp73 isoforms, use TAp73-specific antibodies

• For specific detection of ΔNp73, use ΔNp73-specific antibodies, although these may require higher concentrations (up to 3 μg/ml) for detection

Staining patterns to expect:

• TAp73: Nuclear staining in multiciliated cells (bronchus, fallopian tube, secretory endometrium)

• p73α: More widespread, including nuclei of basal layer cells in squamous epithelia (oesophagus, skin, cervix) and basal cells in bronchus

• ΔNp73: May be difficult to detect in normal tissues despite robust recognition in transfected cell blocks

Clinical relevance in cancer tissues:
In cervical squamous cell carcinomas, p73α expression has been found in 79% of cases, with staining distribution in basal cells correlating with lower tumor grade. TAp73 was found in 17% of these tumors with no specific association with clinicopathological features .

What controls should be included when using TP73 antibodies to ensure reliable results?

Proper experimental controls are essential for confident interpretation of TP73 antibody results:

Positive controls:

• Transfected cell lines: Cells overexpressing specific TP73 isoforms provide the most reliable positive controls

• Known positive tissues: Based on the antibody and isoform:

  • For TAp73: Multiciliated epithelia (bronchus, fallopian tube)

  • For p73α: Basal layer of squamous epithelia and multiciliated cells

• Cell lines with known endogenous expression: MCF-7, HeLa, HEK-293, Jurkat, HSC-T6, NIH/3T3, and RAW 264.7 cells show detectable TP73 expression

Negative controls:

• Isotype controls: Using matching IgG class antibodies (e.g., Mouse IgG1 for TP73 monoclonal antibodies)

• Tissues known to be negative: Certain tissues consistently show negative staining for all p73 isoforms

• Cross-reactivity controls: Testing against related proteins (p53, p63 isoforms) to confirm specificity

Technical controls:

• Antibody titration: Sequential dilutions to determine optimal concentration

• Secondary antibody only: To assess non-specific binding

• Blocking peptide competition: Using the immunizing peptide to confirm specificity

These comprehensive controls help distinguish true staining from artifacts and ensure reproducible, reliable results across experiments.

How can researchers effectively distinguish between closely related TP73 isoforms?

Discriminating between closely related TP73 isoforms requires specialized approaches:

Antibody-based discrimination:

• Isoform-specific antibodies:

  • TAp73-specific antibodies (e.g., TAp73-1.1) recognize only TAp73 isoforms through their unique N-terminal domain

  • ΔNp73-specific antibodies (e.g., ΔNp73-1.1, ΔNp73-2.1) recognize only ΔNp73 isoforms

  • p73α-specific antibodies recognize both TAp73α and ΔNp73α through their shared C-terminal domain

• Combined antibody approach:

  • Using multiple antibodies targeting different domains can help determine which isoforms are present

  • For example, positive staining with both p73α and TAp73 antibodies indicates TAp73α expression

Molecular technique supplementation:

• RT-PCR with isoform-specific primers: To detect specific mRNA variants

• Immunoprecipitation followed by mass spectrometry: For definitive protein identification

• RNA immunoprecipitation (RIP): For studying RNA-protein interactions involving specific TP73 isoforms

Western blotting refinements:
Strategic use of gel percentage and running conditions can help resolve closely migrating isoforms. For example, TAp73α (calculated MW 70 kDa) can be distinguished from ΔNp73α based on their slight molecular weight differences .

What is the significance of TP73 isoform distribution in normal tissues and cancer?

The tissue-specific distribution of TP73 isoforms provides important insights into their biological roles:

Normal tissue distribution patterns:

Cancer-related findings:
In cervical squamous cell carcinomas:

• p73α expression was found in 79% of cases

• The distribution pattern of p73α in basal cells correlated with lower tumor grade

• Statistical analysis showed significant association (p=0.009) between basal p73α expression pattern and lower grade (1/2) tumors

• TAp73 was found in only 17% of tumors with no correlation to clinicopathological features

These findings suggest distinct roles for TP73 isoforms in cancer progression, with p73α potentially serving as a prognostic marker in certain contexts.

How can TP73 antibodies be used in complex experimental approaches beyond standard applications?

Advanced research applications of TP73 antibodies extend beyond basic Western blotting and immunohistochemistry:

RNA immunoprecipitation (RIP):
TP73 antibodies have been successfully used in RIP applications to study RNA-protein interactions . This technique allows researchers to identify RNA molecules that interact with specific TP73 isoforms, providing insights into post-transcriptional regulation mechanisms.

Chromatin immunoprecipitation (ChIP):
TP73 antibodies can be adapted for ChIP experiments to identify genomic binding sites, helping elucidate the transcriptional regulatory networks controlled by different TP73 isoforms.

Tissue microarray (TMA) analysis:
For high-throughput analysis of TP73 expression across multiple tumor samples, antibodies can be applied to TMAs. This approach has revealed correlations between p73α expression patterns and tumor grade in cervical cancer .

Multiplexed immunofluorescence:
Combining TP73 isoform-specific antibodies with markers for proliferation (Ki67), differentiation, or other p53 family members can provide deeper insights into the complex interrelationships between these proteins in normal and diseased tissues.

In situ proximity ligation assay (PLA):
This technique can detect protein-protein interactions involving TP73 isoforms in intact cells and tissues, helping map the interactome of different variants.

What are common challenges in detecting TP73 isoforms and how can they be overcome?

Researchers face several challenges when working with TP73 antibodies:

Challenge: Low endogenous expression levels

• Solution: Use sensitive detection methods such as enhanced chemiluminescence or fluorescent secondary antibodies

• Strategy: Concentrate protein samples through immunoprecipitation before Western blotting

• Approach: For IHC, optimize antigen retrieval and signal amplification methods

Challenge: Cross-reactivity with related proteins

• Solution: Use thoroughly validated isoform-specific antibodies

• Strategy: Include appropriate controls expressing only specific isoforms

• Approach: Confirm results using multiple antibodies targeting different epitopes

Challenge: Difficulty detecting ΔNp73 in normal tissues

• Solution: Increase antibody concentration (up to 3 μg/ml) for IHC applications

• Strategy: Use positive control tissues or cell blocks alongside test samples

• Note: Research suggests ΔNp73 may genuinely be a minor form in human tissues

Challenge: Differential protein stability affecting detection

• Observation: In transfection experiments, ΔNp73 levels appear higher than TAp73, and TAp73β/γ higher than TAp73α

• Solution: Consider protein stabilization approaches or proteasome inhibitors if studying less stable isoforms

• Strategy: Normalize results carefully when comparing different isoforms

How should researchers interpret discrepancies between different TP73 antibody staining patterns?

When different TP73 antibodies produce seemingly contradictory results, systematic analysis is required:

Antibody epitope considerations:

• Antibodies targeting different domains will produce different staining patterns

• p73α antibodies detect both TAp73α and ΔNp73α isoforms

• TAp73-specific antibodies detect only TAp73 variants

• Discrepancies may reflect genuine biological differences in isoform expression

Technical interpretation guide:

• If p73α staining is positive but TAp73 staining is negative: Suggests presence of ΔTAp73α

• If both p73α and TAp73 staining are positive: Suggests presence of TAp73α

• If p73α staining is negative but another p73 antibody is positive: Consider presence of β, γ or other C-terminal variants

Validation approaches:

• Compare staining patterns with mRNA expression data

• Use multiple antibodies targeting different epitopes

• Consider the biological context and existing literature on expected expression patterns

For example, in normal tissues, TAp73 staining is restricted to multiciliated cells, while p73α staining is more widespread, including basal layer cells in squamous epithelia. This pattern reflects genuine biological differences rather than technical artifacts .

What statistical approaches are appropriate when analyzing TP73 expression in tissue samples?

When analyzing TP73 expression in tissue samples, particularly in cancer research, appropriate statistical methods are essential:

Statistical tests for categorical data:

• Fisher's exact probability test is appropriate for analyzing associations between TP73 expression and categorical variables (e.g., tumor grade, lymph node status)

• This approach was used to identify significant association (p=0.009) between basal p73α expression pattern and lower tumor grade in cervical squamous cell carcinomas

Data categorization approaches:

• For p73α expression in cervical cancer: categorize as "basal" versus "diffuse" pattern

• For TAp73 expression: categorize as "positive" versus "negative"

• For tumor grade analysis: group as lower grade (1/2) versus higher grade (3)

Sample size considerations:
The study examining p73α expression in cervical cancer analyzed 62 cases, providing sufficient statistical power to detect significant associations with histological subtype (p=0.003) and tumor grade (p=0.009) .

Correlation with other markers:
When examining relationships between TP73 expression and other markers (e.g., Ki67), different cut-off values should be tested. For example, no association was found between p73α expression and Ki67 levels, regardless of the percentage cut-off used .

This statistical framework allows for robust analysis of TP73 expression patterns and their relationship to clinicopathological features in research settings.

How might emerging technologies enhance the study of TP73 isoforms?

The field of TP73 research stands to benefit from several emerging technologies:

Single-cell analysis technologies:

• Single-cell RNA sequencing can reveal cell-type specific expression patterns of TP73 isoforms at unprecedented resolution

• Single-cell proteomics may eventually allow detection of protein isoforms in individual cells

• These approaches could further refine our understanding of TAp73 and ΔTAp73 expression in specialized cell populations

CRISPR-based approaches:

• CRISPR/Cas9 genome editing can create isoform-specific knockouts to study functional consequences

• CRISPRa/CRISPRi systems can selectively modulate expression of specific isoforms

• CRISPR base editors can introduce specific mutations to study structure-function relationships

Spatial transcriptomics/proteomics:

• These technologies can map TP73 isoform expression within the tissue architecture

• This could extend current knowledge of TAp73 in multiciliated cells and ΔTAp73 in basal/reserve cells by providing spatial context

Advanced protein imaging:

• Super-resolution microscopy may reveal subcellular localization patterns of different TP73 isoforms

• Live-cell imaging with tagged TP73 variants could track dynamic changes in localization and interactions

These technologies promise to address remaining questions about the complex biology of TP73 isoforms in normal development and disease.

What are the implications of TP73 isoform distribution for cancer diagnosis and treatment?

The differential expression of TP73 isoforms in cancer has several potential clinical applications:

Diagnostic applications:

• p73α expression patterns (basal vs. diffuse) correlate with tumor grade in cervical squamous cell carcinoma, suggesting potential use as a diagnostic or prognostic marker

• The significant association (p=0.009) between basal p73α expression and lower grade tumors suggests utility in refining histopathological classification

Therapeutic implications:

• The opposing functions of TAp73 (potentially tumor-suppressive) and ΔTAp73 (potentially oncogenic) suggest that therapeutic approaches might aim to:

  • Restore or enhance TAp73 activity

  • Inhibit ΔTAp73 function

  • Alter the ratio between these isoforms

Biomarker development:

• Isoform-specific antibodies could be developed as companion diagnostics for therapies targeting the p53 family

• Expression patterns might predict response to conventional treatments like chemotherapy and radiation

Research needs:
Further studies are needed to establish whether p73α expression patterns have prognostic value beyond correlation with tumor grade. While the current data show associations with histopathological features, direct relationships with clinical outcomes (progression, disease-specific mortality) were not statistically significant in the available research .

How does TP73 research intersect with studies of related p53 family members?

TP73 research exists within the broader context of the p53 family, with important interconnections:

Structural and functional parallels:

• All p53 family members (p53, p63, p73) produce multiple isoforms through alternative promoters and splicing

• Similar to TP73, p63 produces TA and ΔN variants with distinct functions

• Understanding common mechanisms across the family may reveal conserved regulatory principles

Cross-regulation within the family:

• p53 family members can form heterocomplexes that affect transcriptional activity

• They may compete for binding to shared target genes

• Antibody specificity is crucial to distinguish between family members in experimental settings

Complementary tissue-specific roles:

• While TAp73 marks multiciliated cells, p63 (particularly ΔNp63) is a key regulator in epithelial stem cells

• p53 functions primarily in stress response and DNA damage pathways

• Together, these proteins form a regulatory network controlling development, differentiation, and tumor suppression

Implications for research methodology:
When studying TP73, researchers should consider potential interactions with or compensation by other p53 family members. Antibody validation must include testing for cross-reactivity with p53 and p63 isoforms, as demonstrated in the comprehensive validation approach used for the antibodies described in the research literature .

Understanding these interconnections enriches the interpretation of TP73 research findings and places them within the broader context of cellular regulation.